II. Mechanism
- Extracellular CTLA4 fused to Fc of IgG1
- Inhibits CD28 to CD80/CD66 binding
- Increases T-Cell Activation threshold and inhibits T-Cell proliferation
III. Dosing
- IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
- Initial: 0, 2 and 4 months and then every 4 months
IV. Indications
- Refractory Rheumatoid Arthritis
V. Contraindications
- Do not use with TNF Antagonist agent, and probably Anankira
- Live virus Vaccine within the last 3 months